The potential role of kallistatin as a new biomarker in non-invasivediagnostics of non-alcoholic fatty liver disease with hypertension

Prof. O.Ya. Babak, prof. N.M. Zhelezniakova, as.prof. A.O. Rozhdestvenska

Kharkiv National Medical University

It is known that non-alcoholic fatty liver disease (NAFLD) is recognized as one of the most common diseases in the 21st century. A variant of the comorbidity is the combination of NAFLD with the hypertension (HT) increasing the risks of non-alcoholic steatosis progressing to non-alcoholic steatohepatitis (NASH). The disadvantages of a liver biopsy determine the relevance of searching for new non-invasive methods, that could confirm the diagnosis, determine the form, grade and severity of NAFLD. The review is devoted to the study of potential use of anti-inflammatory biomarker kallistatin for non-invasive diagnostics to assess fibrotic changes in liver and predict disease severity in non-alcoholic fatty liver patients with hypertension.

Key Words: kallistatin, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, hypertension, biomarker, non-invasive diagnostics.

https://dx.doi.org/10.15407/internalmed2019.02.018

Download.PDF

For citing:

  1. Бабак, О.Я. Потенційна роль калістатину як нового біомаркера неінвазивної діагностики неалкогольної жирової хвороби печінки на тлі гіпертонічної хвороби / О.Я. Бабак, Н.М. Железнякова, А.О. Рождественська // Східноєвропейський журнал внутрішньої та сімейної медицини. – 2019. – № 2. – С. 18-23. doi: 10.15407/internalmed2019.02.018.
  2. Babak OYa, Zhelezniakova NM, Rozhdestvenska AO. [The potential role of kallistatin as a new biomarker in non-invasive diagnostics of non-alcoholic fatty liver disease with hypertension]. Shidnoevr. z. vnutr. simejnoi med. 2019;2:18-23. doi: 10.15407/internalmed2019.02.018.

References:

1. Babak OYa, Lapshyna KA, Chernyak AM. Kompleksne likuvannja nealkogholjnoji zhyrovoji khvoroby pechinky: dosvid zastosuvannja ghepatoprotektoriv [Complex treatment of non-alcoholic fatty liver disease: experience of the use of hepatoprotectors]. Suchasna ghastroenterologhija. 2018;2:32-36. Ukrainian.

2. Babak OJa. Nealkogol’naja zhirovaja bolezn’ pecheni i kardiovaskuljarnyj risk: sovremennyj vzgljad na problemu. Optimizacija terapii. News of medicine and pharmacy. 2012;8:12-14. Ukrainian.

3. Zemlіanіtsyna OV, Dunaeva ІP, Savenkov VІ, Sinaіko VM, Maltseva YuV, Kravchun NO. Nealkogholjna zhyrova khvoroba pechinky: poshyrenistj, etiologhija i patoghenez, naprjamky diaghnostyky ta terapiji (oghljad literatury ta vlasni dani) [Non-alcoholic fatty liver disease: prevalence, etiology, pathogenesis, approaches to the dіagnosis and therapy (literature review and own data)]. International Journal of Endocrinology (Ukraine). 2018;7:684-693. Ukrainian. DOI: https://doi.org/10.22141/2224-0721.14.7.2018.148777
https://doi.org/10.22141/2224-0721.14.7.2018.148777

4. Fadeenko GD, Kushnir IE, Mozhina TL, Chernova VM, Solomentseva TA. Rol syvorotochnyh biomarkerovv diagnostike nealkogolnoj zhirovoj bolezni pecheni [The role of serum biomarkers in the diagnosis of nonalcoholic fatty liver disease]. Suchasna gastroenterologіja. 2019;3:58-65. Russian. doi.org/10.30978/mg-2019-3-58.
https://doi.org/10.30978/MG-2019-3-58

5. Al-Shimaa M A, Moustafa S A, Noha MS, Marwa SS. Evaluation of clinical significance of kallistatin and macrophage inflammatory protein-1b for the diagnosis of liver cirrhosis and hepatocellular carcinoma in Egyptian patients. Research Journal of Pharmacy and Technology. 2019;12(1):43-49. DOI:10.5958/0974-360x.2019.00009.x
https://doi.org/10.5958/0974-360X.2019.00009.X

6. Benedict M, Zhang X. Non-alcoholic fatty liver disease: An expanded review. World Journal of Hepatology. 2017;9(16):715. DOI:10.4254/wjh.v9.i16.715
https://doi.org/10.4254/wjh.v9.i16.715

7. Borges-Canha M, João Sérgio Neves, Libânio D, Von-Hafe M, Vale C, Araújo-Martins M, Leite AR, Pimentel-Nunes P, Carvalho D, Leite-Moreira A. Association between nonalcoholic fatty liver disease and cardiac functionand structure – a meta-analysis. Endocrine. 2019;66(3):467-476. DOI:10.1007/s12020-019-02070-0.
https://doi.org/10.1007/s12020-019-02070-0

8. Chao J, Bledsoe G, Chao L. Protective Role of Kallistatin in Vascular and Organ Injury. Hypertension. 2016;68(3):533-541. DOI:10.1161/hypertensionaha.116.07861
https://doi.org/10.1161/HYPERTENSIONAHA.116.07861

9. Chao J, Guo Y, Li P, Chao L. Opposing Effects of Oxygen Regulation on Kallistatin Expression: Kallistatin as a Novel Mediator of Oxygen-Induced HIF-1-eNOS-NO Pathway. Oxidative Medicine and Cellular Longevity. 2017:1-8. DOI:10.1155/2017/5262958
https://doi.org/10.1155/2017/5262958

10. Chao J, Guo Y, Li P, Chao L. Role of Kallistatin Treatment in Aging and Cancer by Modulating miR-34a and miR-21 Expression. Oxidative Medicine and Cellular Longevity.2017:1-7. DOI:10.1155/2017/5025610
https://doi.org/10.1155/2017/5025610

11. Cheng Z, Lv Y, Pang S, Bai R, Wang M, Lin S, Xu T, Spalding D, Habib N, Xu R. Kallistatin, a new and reliable biomarker for the diagnosis of liver cirrhosis. Acta Pharmaceutica Sinica B. 2015;5(3):194-200. DOI:10.1016/j.apsb.2015.02.003
https://doi.org/10.1016/j.apsb.2015.02.003

12. Choudhary NS, Duseja A. Screening of Cardiovascular Disease in Nonalcoholic Fatty Liver Disease: Whom and How? Journal of Clinical and Experimental Hepatology. (Forthcoming 2019). DOI:10.1016/j.jceh.2019.02.005
https://doi.org/10.1016/j.jceh.2019.02.005

13. Dunn W, Xu R, Wingard DL, Rogers C, Angulo P, Younossi ZM, Schwimmer J. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. The American Journal of Gastroenterology. 2008;103(9):2263-2271. DOI:10.1111/j.1572-0241.2008.02034.x
https://doi.org/10.1111/j.1572-0241.2008.02034.x

14. Eckard A R., Cho S, O’Riordan MA, McComsey GA. Kallistatin levels in HIV-infected patients and effects of statin therapy. Biomarkers: biochemical indicators of exposure, response, and susceptibility to chemicals.2017;22(1):55-62. DOI:10.1080/1354750x.2016.1204002
https://doi.org/10.1080/1354750X.2016.1204002

15. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASLEASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol.2016;64(6):1388-402. DOI:10.1007/s00125-016-3902-y
https://doi.org/10.1007/s00125-016-3902-y

16. Frühbeck G, Gómez-Ambrosi J, Rodríguez A, Ramírez B, Valentí V, Moncada R, Becerril S, Unamuno X, Silva C, Salvador J, Catalán V. Novel protective role of kallistatin in obesity by limiting adipose tissue low grade inflammation and oxidative stress. Metabolism.2018;87:123-135.DOI:10.1016/j.metabol.2018.04.004
https://doi.org/10.1016/j.metabol.2018.04.004

17. Gao L, Li P, Zhang J, Hagiwara M, Shen D, Bledsoe G, Chang E, Chao L, Chao J. Novel Role of Kallistatin in Vascular Repair by Promoting Mobility, Viability, and Function of Endothelial Progenitor Cells. Journal of the American Heart Association.2014;3(5). DOI:10.1161/jaha.114.001194
https://doi.org/10.1161/JAHA.114.001194

18. Gateva A, Assyov Y, Velikova T, Kamenov Z. Increased kallistatin levels in patients with obesity and prediabetes compared to normal glucose tolerance. Endocrine Research. 2017;42(2):163-168. doi: 10.1080/07435800.2017.1286671.
https://doi.org/10.1080/07435800.2017.1286671

19. Guo Y, Chao L, Chao J. Kallistatin attenuates endothelial senescence by modulating Let-7gmediated miR-34a-SIRT1-eNOS pathway. J Cell Mol Med. 2018;1-12. DOI:10.1111/jcmm.13734
https://doi.org/10.1111/jcmm.13734

20. Halla MR, Fawzy AA, Nabila AM. Evaluation of kallistatin as a biomarker in chronic hepatitis c patients, World journal of pharmacy and pharmaceutical sciences. 2017;6(9):150-174. DOI:10.20959/wjpps20179-10058
https://doi.org/10.20959/wjpps20179-10058

21. Hartleb M, Barański K, Zejda J, Chudek J, Więcek A. Nonalcoholic fatty liver (NAFL) and advanced fibrosis in the elderly: results from a community based Polish surveyLiver Int.2017;37(11):1706-1714. DOI:10.1111/liv.13471
https://doi.org/10.1111/liv.13471

22. Huang X, Wang X, Xie X. Kallistatin protects against bleomycin-induced idiopathic pulmonary fibrosis by inhibiting angiogenesis and inflammation. Am J Transl Res.2017;9(3):999-1011.

23. Karbasi-Afshar R, Saburi A, HosseinKhedmat H. Cardiovascular Disorders in the Context of NonAlcoholic Fatty Liver Disease: A Literature Review. The Journal of Tehran University Heart Center. 2014;9(1):1-8.

24. Kargulewicz A, Stankowiak-Kulpa H, Grzymisławski M. Assessment of the prevalence of nonalcoholic fatty liver disease among obese polish people and the estimation of the knowledge of nutritional recommendations. Nowiny Lekarskie. 2012;81:611-619.

25. Li B, Sheng Z, Liu C, Qian L, Wu Y, Wu Y, Ma G, Yao Y. Kallistatin Inhibits Atherosclerotic inflammation by regulating macrophage polarization. Human Gene Therapy. 2019;30(3):339-351. DOI:10.1089/hum.2018.084
https://doi.org/10.1089/hum.2018.084

26. Lin W-C, Chen C-W, Chao L, Chao J, Lin Y-S (2017) Plasma kallistatin in critically ill patients with severe sepsis and septic shock. PLoS ONE 12(5): e0178387. https://doi.org/10.1371/journal.pone.0178387
https://doi.org/10.1371/journal.pone.0178387

27. Lucas C, Lucas G, Lucas N, Krzowska-Firych J, Tomasiewicz K. A systematic review of the present and future of non-alcoholic fatty liver disease. Clinical and Experimental Hepatology. 2018;4(3):165-174. DOI:10.5114/ceh.2018.78120
https://doi.org/10.5114/ceh.2018.78120

28. Ma C, Yin H, Zhong J, Zhang Y, Luo C, Che D, Fang Z, Li L, Qin S, Liang J, Qi W, Yang Z, Zhou T, Ma J, Yang X, Gao G. Kallistatin exerts antilymphangiogenic effects by inhibiting lymphatic endothelial cell proliferation, migration and tube formation. International Journal of Oncology. 2017;50(6):2000-2010. DOI:10.3892/ijo.2017.3972
https://doi.org/10.3892/ijo.2017.3972

29. Maida M, Macaluso FS, Salomone F, Petta S. Non-Invasive Assessment of Liver Injury in Non-Alcoholic Fatty Liver Disease: A Review of Literature. Current Molecular Medicine. 2016;16(8):721-737. DOI:10.2174/1566524016666161004143613
https://doi.org/10.2174/1566524016666161004143613

30. Nallagangula KS, Shashidhar KN, Lakshmaiah V, Muninarayana C. Cirrhosis of liver: Interference of serpins in quantification of SERPINA4 – A preliminary study. Practical laboratory medicine. 2017;9:53-57. DOI:10.1016/j.plabm.2017.10.002
https://doi.org/10.1016/j.plabm.2017.10.002

31. Ooi G J, Mgaieth S, Eslick GD, Burton W, Kemp W, Roberts SK, Brown WA. Systematic review and meta-analysis: non-invasive detection of non-alcoholic fatty liver disease related fibrosis in the obese. Obesity Reviews. 2017;19(2):281-294. DOI:10.1111/obr.12628
https://doi.org/10.1111/obr.12628

32. Prystupa A, Kiciński P, Luchowska-Kocot D, Sak J, Prystupa T, Yung S, Panasiuk L, Załuska W. Factors influencing serum chemerin and kallistatin concentrations n patients with alcohol-induced liver cirrhosis. Annals of agricultural and environmental medicine.2019;26(1):143-147. DOI:10.26444/aaem/100536
https://doi.org/10.26444/aaem/100536

33. Przybylowski P, Wasilewski G, Koc-Żórawska E. Kallistatin Concentration And Hypertension In Heart Transplant Recipients. Transplant Proc. 2018;50 (7):2105-2109. DOI:10.1016/j.transproceed.2018.02.167
https://doi.org/10.1016/j.transproceed.2018.02.167

34. Yao Y, Li B, Liu C, Fu C, Li P, Guo Y, Ma G, Liu N, Chao L, Chao J. Reduced plasma kallistatin is associated with the severity of coronary artery disease, and kallistatin treatment attenuates atherosclerotic plaque formation in mice. J Am Heart Assoc. 2018;7(21). DOI:10.1161/jaha.118.009562
https://doi.org/10.1161/JAHA.118.009562

35. Yiu WH, Wong DW, Wu HJ, Li RX, Yam I, Chan LY, Leung JK, Lan HY, Lai KN, Tang SW. Kallistatin protects against diabetic nephropathy in db/db mice by suppressing AGE-RAGE-induced oxidative stress. Kidney International. 2016;89(2):386-398. DOI:10.1038/ki.2015.331
https://doi.org/10.1038/ki.2015.331